Adverse Drug Interactions: Moving from Perception to Action
The use of highly active antiretroviral therapy (HAART) has been exceptionally effective in improving the mortality and quality of life of patients with HIV/AIDS. Patients who are receiving HAART develop less resistance to individual drugs and typically experience less toxicity than those receiving...
Gespeichert in:
| Veröffentlicht in: | PharmacoEconomics 2010, Vol.28 (1), p.19-22 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 22 |
|---|---|
| container_issue | 1 |
| container_start_page | 19 |
| container_title | PharmacoEconomics |
| container_volume | 28 |
| creator | Mayhew, Ryan McKoy, June M. Luu, Thanh Ha Lopez, Isaac Frick, Melissa Bennett, Charles L. |
| description | The use of highly active antiretroviral therapy (HAART) has been exceptionally effective in improving the mortality and quality of life of patients with HIV/AIDS. Patients who are receiving HAART develop less resistance to individual drugs and typically experience less toxicity than those receiving single-agent therapy. Since HIV/AIDS was first discovered in 1981, 32 agents have been approved by the US FDA, including 26 individual agents and six combinations. However, drug-drug interactions remain a significant concern as new therapeutic agents and classes emerge and fresh combinations of established regimens are explored. |
| doi_str_mv | 10.2165/11530370-000000000-00000 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_222363170</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A221595484</galeid><sourcerecordid>A221595484</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-3bc11f8e39e1908ef73a1489af9ef5fa974e63d25c788c8553c393381e4f63c33</originalsourceid><addsrcrecordid>eNqFUctOBCEQJEbj-wO8mI2eR4GeGeC48Z2YeNEzQbbZHXUewqzGv7fXcdeYmAiBrkBVAQVjI8FPpCiLUyEK4KB4xpdtQGtsWwhlMsmlWv_CPFOl4VtsJ6UnIpSg5CbbkpyLXCvYZgfjyRvGhKPzOJ-Obpoeo_N91TZpj20E95Jw_7vusofLi_uz6-z27urmbHyb-bzUfQaPXoigEQwKwzUGBY68jQsGQxGcUTmWMJGFV1p7XRTgwQBogXkoCcMuOxp8u9i-zjH19qmdx4aOtFJKKIEeQaTjgTR1L2irJrQ93bOukrdjKUVhilznxDr5g0V9gnXl2wZDReu_BHoQ-NimFDHYLla1ix9WcLtI2i6TtqukB0TS60EasUO_0r0_z7oZ0ln2zYKTmqaPBeBkCK6iIWh0i2rofXbW12R1-J3A_LHGycpr-UtEMAMh0VYzxfgT0b_3_ARpIZ1I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222363170</pqid></control><display><type>article</type><title>Adverse Drug Interactions: Moving from Perception to Action</title><source>MEDLINE</source><source>RePEc</source><source>SpringerLink Journals - AutoHoldings</source><creator>Mayhew, Ryan ; McKoy, June M. ; Luu, Thanh Ha ; Lopez, Isaac ; Frick, Melissa ; Bennett, Charles L.</creator><creatorcontrib>Mayhew, Ryan ; McKoy, June M. ; Luu, Thanh Ha ; Lopez, Isaac ; Frick, Melissa ; Bennett, Charles L.</creatorcontrib><description>The use of highly active antiretroviral therapy (HAART) has been exceptionally effective in improving the mortality and quality of life of patients with HIV/AIDS. Patients who are receiving HAART develop less resistance to individual drugs and typically experience less toxicity than those receiving single-agent therapy. Since HIV/AIDS was first discovered in 1981, 32 agents have been approved by the US FDA, including 26 individual agents and six combinations. However, drug-drug interactions remain a significant concern as new therapeutic agents and classes emerge and fresh combinations of established regimens are explored.</description><identifier>ISSN: 1170-7690</identifier><identifier>EISSN: 1179-2027</identifier><identifier>DOI: 10.2165/11530370-000000000-00000</identifier><identifier>PMID: 20014873</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Acquired immune deficiency syndrome ; Adverse and side effects ; AIDS ; AIDS (Disease) ; Anti-HIV Agents - adverse effects ; Antiretroviral drugs ; Antiretroviral Therapy, Highly Active - adverse effects ; Antiviral agents ; Clinical outcomes ; Commentary ; Complications and side effects ; Costs ; Dosage and administration ; Drug Interactions ; Drug therapy ; Drug-Related Side Effects and Adverse Reactions ; Drugs ; Health Administration ; Health Economics ; Highly active antiretroviral therapy ; HIV ; Human immunodeficiency virus ; Humans ; Infections ; Insurance Claim Review ; Medicare ; Medicine & Public Health ; Patient safety ; Pharmacists ; Pharmacoeconomics ; Pharmacoeconomics and Health Outcomes ; Pharmacology ; Pharmacovigilance ; Prescription drugs ; Product safety ; Public Health ; Quality of Life Research ; R&D ; Research & development</subject><ispartof>PharmacoEconomics, 2010, Vol.28 (1), p.19-22</ispartof><rights>Adis Data Information BV 2010</rights><rights>COPYRIGHT 2010 Wolters Kluwer Health, Inc.</rights><rights>Copyright Wolters Kluwer Health Adis International Jan 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c468t-3bc11f8e39e1908ef73a1489af9ef5fa974e63d25c788c8553c393381e4f63c33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.2165/11530370-000000000-00000$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.2165/11530370-000000000-00000$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,4007,4023,27922,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20014873$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://econpapers.repec.org/article/wkhphecon/v_3a28_3ay_3a2010_3ai_3a1_3ap_3a19-22.htm$$DView record in RePEc$$Hfree_for_read</backlink></links><search><creatorcontrib>Mayhew, Ryan</creatorcontrib><creatorcontrib>McKoy, June M.</creatorcontrib><creatorcontrib>Luu, Thanh Ha</creatorcontrib><creatorcontrib>Lopez, Isaac</creatorcontrib><creatorcontrib>Frick, Melissa</creatorcontrib><creatorcontrib>Bennett, Charles L.</creatorcontrib><title>Adverse Drug Interactions: Moving from Perception to Action</title><title>PharmacoEconomics</title><addtitle>Pharmacoeconomics</addtitle><addtitle>Pharmacoeconomics</addtitle><description>The use of highly active antiretroviral therapy (HAART) has been exceptionally effective in improving the mortality and quality of life of patients with HIV/AIDS. Patients who are receiving HAART develop less resistance to individual drugs and typically experience less toxicity than those receiving single-agent therapy. Since HIV/AIDS was first discovered in 1981, 32 agents have been approved by the US FDA, including 26 individual agents and six combinations. However, drug-drug interactions remain a significant concern as new therapeutic agents and classes emerge and fresh combinations of established regimens are explored.</description><subject>Acquired immune deficiency syndrome</subject><subject>Adverse and side effects</subject><subject>AIDS</subject><subject>AIDS (Disease)</subject><subject>Anti-HIV Agents - adverse effects</subject><subject>Antiretroviral drugs</subject><subject>Antiretroviral Therapy, Highly Active - adverse effects</subject><subject>Antiviral agents</subject><subject>Clinical outcomes</subject><subject>Commentary</subject><subject>Complications and side effects</subject><subject>Costs</subject><subject>Dosage and administration</subject><subject>Drug Interactions</subject><subject>Drug therapy</subject><subject>Drug-Related Side Effects and Adverse Reactions</subject><subject>Drugs</subject><subject>Health Administration</subject><subject>Health Economics</subject><subject>Highly active antiretroviral therapy</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infections</subject><subject>Insurance Claim Review</subject><subject>Medicare</subject><subject>Medicine & Public Health</subject><subject>Patient safety</subject><subject>Pharmacists</subject><subject>Pharmacoeconomics</subject><subject>Pharmacoeconomics and Health Outcomes</subject><subject>Pharmacology</subject><subject>Pharmacovigilance</subject><subject>Prescription drugs</subject><subject>Product safety</subject><subject>Public Health</subject><subject>Quality of Life Research</subject><subject>R&D</subject><subject>Research & development</subject><issn>1170-7690</issn><issn>1179-2027</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>X2L</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFUctOBCEQJEbj-wO8mI2eR4GeGeC48Z2YeNEzQbbZHXUewqzGv7fXcdeYmAiBrkBVAQVjI8FPpCiLUyEK4KB4xpdtQGtsWwhlMsmlWv_CPFOl4VtsJ6UnIpSg5CbbkpyLXCvYZgfjyRvGhKPzOJ-Obpoeo_N91TZpj20E95Jw_7vusofLi_uz6-z27urmbHyb-bzUfQaPXoigEQwKwzUGBY68jQsGQxGcUTmWMJGFV1p7XRTgwQBogXkoCcMuOxp8u9i-zjH19qmdx4aOtFJKKIEeQaTjgTR1L2irJrQ93bOukrdjKUVhilznxDr5g0V9gnXl2wZDReu_BHoQ-NimFDHYLla1ix9WcLtI2i6TtqukB0TS60EasUO_0r0_z7oZ0ln2zYKTmqaPBeBkCK6iIWh0i2rofXbW12R1-J3A_LHGycpr-UtEMAMh0VYzxfgT0b_3_ARpIZ1I</recordid><startdate>2010</startdate><enddate>2010</enddate><creator>Mayhew, Ryan</creator><creator>McKoy, June M.</creator><creator>Luu, Thanh Ha</creator><creator>Lopez, Isaac</creator><creator>Frick, Melissa</creator><creator>Bennett, Charles L.</creator><general>Springer International Publishing</general><general>Springer Healthcare | Adis</general><general>Wolters Kluwer Health, Inc</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>DKI</scope><scope>X2L</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0U~</scope><scope>1-H</scope><scope>3V.</scope><scope>4T-</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>L.-</scope><scope>L.0</scope><scope>M0C</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>2010</creationdate><title>Adverse Drug Interactions</title><author>Mayhew, Ryan ; McKoy, June M. ; Luu, Thanh Ha ; Lopez, Isaac ; Frick, Melissa ; Bennett, Charles L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-3bc11f8e39e1908ef73a1489af9ef5fa974e63d25c788c8553c393381e4f63c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Adverse and side effects</topic><topic>AIDS</topic><topic>AIDS (Disease)</topic><topic>Anti-HIV Agents - adverse effects</topic><topic>Antiretroviral drugs</topic><topic>Antiretroviral Therapy, Highly Active - adverse effects</topic><topic>Antiviral agents</topic><topic>Clinical outcomes</topic><topic>Commentary</topic><topic>Complications and side effects</topic><topic>Costs</topic><topic>Dosage and administration</topic><topic>Drug Interactions</topic><topic>Drug therapy</topic><topic>Drug-Related Side Effects and Adverse Reactions</topic><topic>Drugs</topic><topic>Health Administration</topic><topic>Health Economics</topic><topic>Highly active antiretroviral therapy</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infections</topic><topic>Insurance Claim Review</topic><topic>Medicare</topic><topic>Medicine & Public Health</topic><topic>Patient safety</topic><topic>Pharmacists</topic><topic>Pharmacoeconomics</topic><topic>Pharmacoeconomics and Health Outcomes</topic><topic>Pharmacology</topic><topic>Pharmacovigilance</topic><topic>Prescription drugs</topic><topic>Product safety</topic><topic>Public Health</topic><topic>Quality of Life Research</topic><topic>R&D</topic><topic>Research & development</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mayhew, Ryan</creatorcontrib><creatorcontrib>McKoy, June M.</creatorcontrib><creatorcontrib>Luu, Thanh Ha</creatorcontrib><creatorcontrib>Lopez, Isaac</creatorcontrib><creatorcontrib>Frick, Melissa</creatorcontrib><creatorcontrib>Bennett, Charles L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>RePEc IDEAS</collection><collection>RePEc</collection><collection>CrossRef</collection><collection>Global News & ABI/Inform Professional</collection><collection>Trade PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Professional Standard</collection><collection>ABI/INFORM Global</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>PharmacoEconomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mayhew, Ryan</au><au>McKoy, June M.</au><au>Luu, Thanh Ha</au><au>Lopez, Isaac</au><au>Frick, Melissa</au><au>Bennett, Charles L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adverse Drug Interactions: Moving from Perception to Action</atitle><jtitle>PharmacoEconomics</jtitle><stitle>Pharmacoeconomics</stitle><addtitle>Pharmacoeconomics</addtitle><date>2010</date><risdate>2010</risdate><volume>28</volume><issue>1</issue><spage>19</spage><epage>22</epage><pages>19-22</pages><issn>1170-7690</issn><eissn>1179-2027</eissn><abstract>The use of highly active antiretroviral therapy (HAART) has been exceptionally effective in improving the mortality and quality of life of patients with HIV/AIDS. Patients who are receiving HAART develop less resistance to individual drugs and typically experience less toxicity than those receiving single-agent therapy. Since HIV/AIDS was first discovered in 1981, 32 agents have been approved by the US FDA, including 26 individual agents and six combinations. However, drug-drug interactions remain a significant concern as new therapeutic agents and classes emerge and fresh combinations of established regimens are explored.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>20014873</pmid><doi>10.2165/11530370-000000000-00000</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1170-7690 |
| ispartof | PharmacoEconomics, 2010, Vol.28 (1), p.19-22 |
| issn | 1170-7690 1179-2027 |
| language | eng |
| recordid | cdi_proquest_journals_222363170 |
| source | MEDLINE; RePEc; SpringerLink Journals - AutoHoldings |
| subjects | Acquired immune deficiency syndrome Adverse and side effects AIDS AIDS (Disease) Anti-HIV Agents - adverse effects Antiretroviral drugs Antiretroviral Therapy, Highly Active - adverse effects Antiviral agents Clinical outcomes Commentary Complications and side effects Costs Dosage and administration Drug Interactions Drug therapy Drug-Related Side Effects and Adverse Reactions Drugs Health Administration Health Economics Highly active antiretroviral therapy HIV Human immunodeficiency virus Humans Infections Insurance Claim Review Medicare Medicine & Public Health Patient safety Pharmacists Pharmacoeconomics Pharmacoeconomics and Health Outcomes Pharmacology Pharmacovigilance Prescription drugs Product safety Public Health Quality of Life Research R&D Research & development |
| title | Adverse Drug Interactions: Moving from Perception to Action |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T08%3A13%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adverse%20Drug%20Interactions:%20Moving%20from%20Perception%20to%20Action&rft.jtitle=PharmacoEconomics&rft.au=Mayhew,%20Ryan&rft.date=2010&rft.volume=28&rft.issue=1&rft.spage=19&rft.epage=22&rft.pages=19-22&rft.issn=1170-7690&rft.eissn=1179-2027&rft_id=info:doi/10.2165/11530370-000000000-00000&rft_dat=%3Cgale_proqu%3EA221595484%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=222363170&rft_id=info:pmid/20014873&rft_galeid=A221595484&rfr_iscdi=true |